SEC Tracker
Get the app

Altimmune ALT

Altimmune draws $10M in loan Tranche Three

Item 2.03 Takes on debt

Form
8-K
Filed
Importance
Notable
  1. Drawn $10.0 million under $125.0 million Loan Agreement
  2. Amortization Date extended to June 1, 2028
  3. Tranche Facility Charge of 1.0% netted from funding
  4. End of term charge remains at 6.25%

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Altimmune files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Prothena Corp Public PRTA public float $327M, Jun 30, 2025
  2. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  3. Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
  4. Aura Biosciences AURA public float $321M, Jun 30, 2025
  5. Amarin AMRN public float $335M, Jun 30, 2025